Although we explicitly elucidated that IKBKE induces RCC progression and sunitinib resistance through the RRM2-AKT pathway, which can be suppressed by CYT387, an IKBKE inhibitor, there are still a few issues to be studied. The gene discussed is AKT1; the disease is renal cell carcinoma.